Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2141.2008.07153.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD33-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.
J Immunother Cancer
September 2025
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Background: Patients with acute myeloid leukemia (AML) are often older, which brings challenges of endurance and persistent efficacy of autologous chimeric antigen receptor (CAR)-T cell therapies. Allogenic CAR-natural killer (NK) cell therapies may offer reduced toxicities and enhanced anti-leukemic potential against AML. CD33 CAR-NK cells have been investigated for AML therapy.
View Article and Find Full Text PDFUnlabelled: There remains an unmet clinical need for improved treatment strategies in Acute Myeloid Leukemia (AML). Although radiopharmaceutical therapies targeting non-cancer-selective antigens have shown promise in AML, their clinical utility is often limited by prolonged bone marrow suppression. Using a unique proteomics-based strategy, we recently identified the active conformation of integrin-β2 (aITGB2) as a novel, tumor-selective target for AML.
View Article and Find Full Text PDFTargeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.
Drug Resist Updat
July 2025
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China; Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou 310014, China; Zhejiang Key Laborato
Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by uncontrolled proliferation of immature myeloid blasts, leading to hematopoietic suppression and bone marrow failure. Advances in understanding the pathogenesis of AML have fueled the development of precision medicine approaches, with notable successes in targeting specific mutant proteins (e.g.
View Article and Find Full Text PDFMachine learning-driven QSAR modeling combined with molecular dynamics suggests high-affinity CD33-targeting peptides for leukemia therapy.
Bioorg Med Chem
November 2025
Stem Cells and Regenerative Medicine Innovation Center, Kerman University of Medical Sciences, Kerman, Iran.
Despite advances in antibody-based therapies for leukemia, significant limitations persist, including immunogenicity, toxicity, and resistance development. To address these challenges, we pursued an innovative peptide-based targeting strategy against CD33, a well-validated surface marker in leukemia. This study establishes a comprehensive pipeline integrating computational design with experimental validation to develop novel CD33-targeting peptides with optimal therapeutic properties.
View Article and Find Full Text PDFCase report: Experience of a rare case of primary acute mast cell leukemia.
Leuk Res Rep
April 2025
Department of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital of Shanxi Medical University), No. 256, Fendong Street, Xiaodian District, Taiyuan, Shanxi 030009, PR China.
Backgrounds: Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.
Case Presentation: We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone.